Bio-Techne Corporation (TECH) Presents At Baird Global Healthcare Conference 2025 Transcript

Bio-Techne CFO James Hippel, speaking at the Baird Global Healthcare Conference, reported Q4 organic growth of 3% and outlined the company's revenue mix, with pharma representing approximately 30%, smaller biotech 20%, and academia 20%. Hippel reiterated expectations that pharma R&D pipeline adjustments, largely influenced by IRA legislation, are anticipated to largely conclude by calendar 2025, leading to a more normalized, pro rata allocation of R&D funding across portfolios.

Analysis

Bio-Techne Corporation (TECH) reported 3% organic growth for its fourth quarter, according to commentary from CFO James Hippel at the Baird Global Healthcare Conference. The company's revenue structure is heavily weighted towards the pharmaceutical and biotechnology sectors, with pharma accounting for approximately 30% of revenue, and smaller biotech firms contributing another 20%. Management reiterated its expectation that significant R&D pipeline reshuffling within the pharma industry, a direct consequence of the IRA legislation that acted as a headwind in 2024, will be largely concluded by the start of calendar year 2025. The key implication of this forecast is a shift towards a more normalized, pro rata allocation of R&D funding from these key clients, suggesting a potential stabilization or recovery in demand for Bio-Techne's products and services from its largest end market.

Key Decisions for Investors

• Investors should monitor leading indicators of pharmaceutical R&D spending in upcoming quarters for evidence that the budget normalization anticipated for 2025 is materializing, as this is a primary catalyst for the company's growth outlook.
• The current 3% organic growth rate should be weighed against the potential for acceleration if the pharma end market recovers as management predicts; the investment thesis is largely dependent on this forward-looking guidance.
• Consider the execution risk that the negative impact of the IRA legislation on pharma R&D budgets may persist longer than the company's 2025 timeline, which could delay a return to stronger growth.